Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Atopic Dermatitis [2017]

    ... older, more toxic immunosuppressant options will lose ground as treating physicians seek better efficacy and safety elsewhere. But as the market evolves, and more treatments are approved, clinical and commercial differentiation will become key. Key ... Read More

  • NPS+ (US) [CLL]

    ... these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? ... Read More

  • NPS+ (EU5) [CLL]

    ... these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? ... Read More

  • NPS+ Type 2 Diabetes Mellitus [2017] US

    ... 2 Diabetes Mellitus (T2DM). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of ... Read More

  • NPS+ Type 2 Diabetes Mellitus [2017] EU5

    ... 2 Diabetes Mellitus (T2DM). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of ... Read More

  • Market Access Impact (US) [Myeloma]

    ... brands lose market share because of them. According to the medical oncologists and haematologists we surveyed, that’s a problem with no single solution; many of them experience as many as 2 different barriers with any ... Read More

  • Rheumatoid Arthritis [2017]: Bulletin #2

    ... expert opinions on; Johnson & Johnson announcing the FDA’s rejection of Plivensia (sirukumab); Can-Fite concluding its cardiodynamic trial for piclidenoson (CF 101) and being given approval to begin a global Phase III trial in patients ... Read More

  • Type 2 Diabetes Mellitus [2017]

    ... molecules. While the wide array of treatment options – including SGLT-2 inhibitors, GLP-1 agonists and newer insulin therapies – provide individualised therapy, unmet needs persist in the market for effective modalities that can provide optimal ... Read More

  • Payer attitudes to Orphan Drug pricing

    ... for orphan drug designation have reached unprecedented levels and the high cost of these specialist treatments is swallowing up a larger and larger share of the drug funding pot. Payers are not happy and clearly ... Read More

  • Medical Affairs Reputations (US) [CLL]

    ... and haematologists, the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians ... Read More

  • Multiple Sclerosis [2016]: Bulletin #3

    ... (MS) treatment landscape. Topics covered include; Roche reporting that a German patient with MS has developed progressive multifocal leukoencephalopathy (PML) following three years of treatment with Tysabri (natalizumab; Biogen) and one dose of Ocrevus (ocrelizumab); ... Read More

  • NPS+ (EU5) [Haemophilia A]

    ... brands. Nearly 45% of the haematologists we surveyed say they’re not satisfied with current options, and eight of the nine brands we asked them about earned negative satisfaction scores. The good news is, brand owners ... Read More

  • Medical Affairs Reputations (US) [Growth Hormone Deficiency]

    ... growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, and the United Kingdom) are doing a passable job, they may be letting doctors down in other ways. From not valuing doctors’ time enough ... Read More

  • Market Access Impact (EU5) [NSCLC]

    ... for market share, but one of them benefits more from market barriers that prevent oncologists from prescribing competing treatments. Eliminating those barriers could help the other leading brand take a narrow, but significant lead. Get ... Read More

  • Breast Cancer [2017]: Bulletin #1

    ... announcing results from the Phase III APHINITY study of Perjeta (pertuzumab) as an adjuvant therapy for BC; Merck & Co. announcing data from the Keytruda (pembrolizumab) I-SPY 2 study; as well as the US approval ... Read More

  • Bladder Cancer [2017]

    ... have emerged from the development pipeline. Five PD-1/PD-L1 immune checkpoint inhibitors have been approved but how are they set to impact treatment pathways? Which checkpoint inhibitor do the key opinion leaders (KOLs) think will dominate ... Read More

  • Payer Insights: RA [2016]: Bulletin #3

    ... and Sandoz (Novartis)’ Rixathon; approvals of biosimilar anti-TNF therapies in the EU/US with Merck & Co. launching Renflexis (biosimilar infliximab) in the US at a 35 percent discount to the wholesale acquisition cost (WAC) of ... Read More

  • NPS+ (US) [RA]

    ... start to see the first changes in perception amongst doctors. ‘Old faithful’ choices are considered alongside ‘the great unknown’ and market share is shifting. How well are established RA brands faring in the loyalty and ... Read More

  • NPS+ (EU5) [RA]

    ... now start to see a shift in perception amongst doctors. ‘Old faithful’ choices are considered against the newcomers and for some, the jury is still out. How well are established RA brands faring in the ... Read More

  • NASH [2017]: Bulletin #1

    ... on the recent positive recommendation by a data safety monitoring board (DSMB) for the continuation of the RESOLVE-IT Phase III trial with Genfit Pharmaceuticals’ elafibranor without any modifications. KOLs discuss the positive Phase II data ... Read More

  • NSCLC [2017]

    ... first-line treatment. Merck & Co. have a head start in this setting with recent approvals for Keytruda; however, BMS, AstraZeneca, Roche and Merck Group/Pfizer still have much to play for. As fist-line treatment options expand, ... Read More

  • Cystic Fibrosis [2017]: Bulletin #2

    ... that it has commenced screening in Europe in the Phase III non-inferiority RESULT study comparing the pancreatic enzyme replacement therapy (PERT) Sollpura to Pancreaze for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF); Protalix ... Read More

  • AML [2017]: Bulletin #2

    ... Seattle Genetics reporting the termination of the Phase III CASCADE study with its anti-CD33 agent vadastuximab talirine (SGN-CD33A) as a front-line approach in older patients with AML; the FDA’s Oncologic Drugs Advisory Committee (ODAC) granting ... Read More

  • HNSCC [2017]: Bulletin #2

    ... in combination with Keytruda (pembrolizumab; Merck & Co.) were presented at ASCO 2017; preliminary results from the ongoing Phase I/II ECHO-204 trial of epacadostat plus Opdivo (nivolumab; Bristol-Myers Squibb [BMS]) in patients with solid tumours, ... Read More

  • Medical Affairs Reputations (EU5) [CLL]

    ... haematologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be ... Read More

2 3 4 5 7 9 10 11

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook